石药,ADC“出海”折戟

动脉网
26 Mar

石药集团与Elevation Oncology合作的Claudin 18.2抗体偶联药物EO-3021因临床试验数据不佳,全球开发计划被终止。该药物曾被视为潜力巨大,为石药带来超10亿美元交易,但疗效缺乏竞争力,尤其在美国低表达患者中效果不佳,引发研发人士对药物设计的质疑。同时,Claudin 18.2 ADC药物普遍缺乏长期安全性数据,未来发展仍面临未知与风险。

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10